|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLCE1 |
Gene summary for PLCE1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLCE1 | Gene ID | 51196 |
| Gene name | phospholipase C epsilon 1 | |
| Gene Alias | NPHS3 | |
| Cytomap | 10q23.33 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9P212 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51196 | PLCE1 | A001-C-014 | Human | Colorectum | FAP | 7.27e-30 | -8.46e-01 | 0.0135 |
| 51196 | PLCE1 | A002-C-016 | Human | Colorectum | FAP | 2.08e-36 | -7.59e-01 | 0.0521 |
| 51196 | PLCE1 | A015-C-002 | Human | Colorectum | FAP | 1.75e-27 | -9.86e-01 | -0.0763 |
| 51196 | PLCE1 | A001-C-007 | Human | Colorectum | CRC | 5.99e-25 | -1.20e+00 | 0.1899 |
| 51196 | PLCE1 | A001-C-203 | Human | Colorectum | FAP | 2.47e-12 | -4.89e-01 | -0.0481 |
| 51196 | PLCE1 | A002-C-116 | Human | Colorectum | FAP | 1.54e-44 | -8.38e-01 | -0.0452 |
| 51196 | PLCE1 | A014-C-008 | Human | Colorectum | FAP | 5.47e-15 | -4.87e-01 | -0.191 |
| 51196 | PLCE1 | A018-E-020 | Human | Colorectum | FAP | 1.87e-33 | -8.17e-01 | -0.2034 |
| 51196 | PLCE1 | F034 | Human | Colorectum | FAP | 4.39e-24 | -6.66e-01 | -0.0665 |
| 51196 | PLCE1 | F072B | Human | Colorectum | FAP | 1.31e-31 | -8.24e-01 | 0.257 |
| 51196 | PLCE1 | CRC-1-8810 | Human | Colorectum | CRC | 4.98e-77 | -1.36e+00 | 0.6257 |
| 51196 | PLCE1 | CRC-3-11773 | Human | Colorectum | CRC | 1.37e-63 | -1.24e+00 | 0.2564 |
| 51196 | PLCE1 | AEH-subject1 | Human | Endometrium | AEH | 6.06e-11 | 3.37e-01 | -0.3059 |
| 51196 | PLCE1 | AEH-subject3 | Human | Endometrium | AEH | 3.14e-03 | 1.90e-01 | -0.2576 |
| 51196 | PLCE1 | AEH-subject5 | Human | Endometrium | AEH | 6.63e-30 | 6.97e-01 | -0.2953 |
| 51196 | PLCE1 | EEC-subject1 | Human | Endometrium | EEC | 8.47e-03 | 2.16e-01 | -0.2682 |
| 51196 | PLCE1 | EEC-subject2 | Human | Endometrium | EEC | 7.38e-31 | 7.20e-01 | -0.2607 |
| 51196 | PLCE1 | EEC-subject4 | Human | Endometrium | EEC | 1.21e-02 | 2.31e-01 | -0.2571 |
| 51196 | PLCE1 | EEC-subject5 | Human | Endometrium | EEC | 2.15e-20 | 5.57e-01 | -0.249 |
| 51196 | PLCE1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.79e-03 | -1.18e-01 | -0.1917 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0038127 | Colorectum | AD | ERBB signaling pathway | 55/3918 | 121/18723 | 1.19e-09 | 8.85e-08 | 55 |
| GO:0007173 | Colorectum | AD | epidermal growth factor receptor signaling pathway | 50/3918 | 108/18723 | 3.08e-09 | 2.07e-07 | 50 |
| GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
| GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
| GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
| GO:0051056 | Colorectum | AD | regulation of small GTPase mediated signal transduction | 94/3918 | 302/18723 | 1.81e-05 | 3.76e-04 | 94 |
| GO:1902743 | Colorectum | AD | regulation of lamellipodium organization | 25/3918 | 54/18723 | 2.63e-05 | 5.01e-04 | 25 |
| GO:1902745 | Colorectum | AD | positive regulation of lamellipodium organization | 19/3918 | 37/18723 | 4.08e-05 | 7.26e-04 | 19 |
| GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
| GO:0097581 | Colorectum | AD | lamellipodium organization | 35/3918 | 90/18723 | 7.39e-05 | 1.18e-03 | 35 |
| GO:0031346 | Colorectum | AD | positive regulation of cell projection organization | 104/3918 | 353/18723 | 8.26e-05 | 1.30e-03 | 104 |
| GO:0010592 | Colorectum | AD | positive regulation of lamellipodium assembly | 15/3918 | 29/18723 | 2.38e-04 | 3.03e-03 | 15 |
| GO:0010591 | Colorectum | AD | regulation of lamellipodium assembly | 18/3918 | 42/18723 | 1.09e-03 | 1.01e-02 | 18 |
| GO:0090257 | Colorectum | AD | regulation of muscle system process | 73/3918 | 252/18723 | 1.46e-03 | 1.24e-02 | 73 |
| GO:0030032 | Colorectum | AD | lamellipodium assembly | 26/3918 | 72/18723 | 2.12e-03 | 1.68e-02 | 26 |
| GO:0046578 | Colorectum | AD | regulation of Ras protein signal transduction | 56/3918 | 189/18723 | 2.85e-03 | 2.14e-02 | 56 |
| GO:0048017 | Colorectum | AD | inositol lipid-mediated signaling | 53/3918 | 182/18723 | 5.35e-03 | 3.52e-02 | 53 |
| GO:0048015 | Colorectum | AD | phosphatidylinositol-mediated signaling | 52/3918 | 178/18723 | 5.37e-03 | 3.54e-02 | 52 |
| GO:0120034 | Colorectum | AD | positive regulation of plasma membrane bounded cell projection assembly | 33/3918 | 105/18723 | 7.49e-03 | 4.55e-02 | 33 |
| GO:0045017 | Colorectum | AD | glycerolipid biosynthetic process | 69/3918 | 252/18723 | 8.33e-03 | 4.88e-02 | 69 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
| hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
| hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa049191 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
| hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa040151 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
| hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa049192 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
| hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa040152 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
| hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa049193 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
| hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa040153 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
| hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa049194 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
| hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
| hsa040154 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLCE1 | SNV | Missense_Mutation | novel | c.5357G>A | p.Arg1786Lys | p.R1786K | Q9P212 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| PLCE1 | SNV | Missense_Mutation | c.5692G>C | p.Gly1898Arg | p.G1898R | Q9P212 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A1-A0SN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD | |
| PLCE1 | SNV | Missense_Mutation | c.6235N>A | p.Pro2079Thr | p.P2079T | Q9P212 | protein_coding | tolerated(0.08) | benign(0.279) | TCGA-A1-A0SQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD | |
| PLCE1 | SNV | Missense_Mutation | novel | c.380N>G | p.Asn127Ser | p.N127S | Q9P212 | protein_coding | tolerated_low_confidence(0.19) | benign(0.003) | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD |
| PLCE1 | SNV | Missense_Mutation | c.3342N>T | p.Glu1114Asp | p.E1114D | Q9P212 | protein_coding | tolerated(0.09) | possibly_damaging(0.883) | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| PLCE1 | SNV | Missense_Mutation | c.3628N>A | p.Asp1210Asn | p.D1210N | Q9P212 | protein_coding | tolerated(0.1) | probably_damaging(0.929) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| PLCE1 | SNV | Missense_Mutation | c.5266N>A | p.His1756Asn | p.H1756N | Q9P212 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PLCE1 | SNV | Missense_Mutation | c.4060G>A | p.Glu1354Lys | p.E1354K | Q9P212 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| PLCE1 | SNV | Missense_Mutation | c.1956N>C | p.Arg652Ser | p.R652S | Q9P212 | protein_coding | tolerated(0.06) | probably_damaging(0.984) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | |
| PLCE1 | SNV | Missense_Mutation | c.3655N>A | p.Val1219Ile | p.V1219I | Q9P212 | protein_coding | tolerated(0.13) | benign(0.023) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51196 | PLCE1 | PHOSPHOLIPASE, DRUGGABLE GENOME, ENZYME | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 31327267 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |